Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Boehringer Ingelheim/Pfizer's Spiriva (tiotropium) will corner the chronic obstructive pulmonary disease (COPD) drug market with a 45% share in 2012. Already launched in Germany, Spain, and the United Kingdom, it will quickly become the gold-standard therapy for COPD -- and will command a premium price -- when it launches in the United States, France, Italy, and Japan in 2004.

The new Pharmacor study entitled Chronic Obstructive Pulmonary Disease also finds that physicians ranked more-effective strategies for smoking cessation as the number one unmet need in COPD management today.

"Smoking cessation is the first and most important intervention in COPD treatment and has been shown to slow long-term decline in lung capacity," said Cynthia Mundy, analyst at Decision Resources. "Unfortunately, prolonged abstinence from smoking is exceedingly difficult, and experts express dissatisfaction with existing smoking cessation aids."

About Chronic Obstructive Pulmonary Disease

COPD is a group of slowly progressive disorders characterized by airflow obstruction. COPD is a major medical problem that exacts a massive toll in terms of patient suffering and cost of care. Primarily a disease of cigarette smokers, COPD affects nearly 50 million people in the major pharmaceutical markets (United States, France, Germany, Spain, Italy, Japan, and the United Kingdom).

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Ferrer Internacional's CerAxon will Corner the Neuroprotectant Drug Market in 2013

View Now